Molecular mechanisms of cisplatin resistance

Molecular mechanisms of cisplatin resistance in cervical cancer

Patients with advanced or recurrent cervical cancer have poor prognosis, and their 1-year survival is only 10%-20%. Chemotherapy is considered as the standard treatment for patients with advanced or recurrent cervical cancer, and cisplatin appears to treat the disease effectively. However, resistance to cisplatin may develop, thus substantially compromising the efficacy of cisplatin to treat ad...

Molecular mechanisms of cisplatin resistance in bladder cancer.

Metastatic disease is the most common mechanism of death in patients with advanced bladder cancer. As for most solid tumors, chemotherapy remains the only realistic option for palliating or curing metastatic disease. However, bladder cancer is characterized by chemoresistance. Only modest response rates are obtained using multiagent regimens including cisplatin. These low response rates and the...

Molecular mechanisms involved in multidrug resistance in breast cancer therapy

Breast cancer is the most prevalent cancer in women. Chemotherapy is the main strategy in the treatment of this disease especially in the advanced form of the disease. Despite the recent progress in the development of new chemotherapy, the effectiveness of these drugs has dramatically reduced due to multidrug resistance. The phenotype of multidrug resistance (MDR) can occur through different me...

Acute Nephrotoxicity of Cisplatin: Molecular mechanisms Authors

Nephrotoxic drugs are responsible for approximately 20% of the episodes of acute kidney injury (AKI) in hospital and outpatient settings. Among elderly individuals, the incidence of drug-induced nephrotoxicity can be as high as 66%. Cisplatin (cis-diamminedichloroplatinum II CDDP) is an oncologic medication included in most chemotherapy regimens for solid or hematologic tumors. Cisplatin’s anti...

Molecular mechanisms of drug resistance.